Nautilus Biotechnology Inc.
Organization details
- Legal name
- Nautilus Biotechnology Inc.
- Former names
- ARYA Sciences Acquisition Corp III
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Information Technology
- SIC code
- 3826 — Laboratory Analytical Instruments
- Headquarters city
- Seattle
- Headquarters state / province
- Washington
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- NAUT
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001808805
- EIN
- 98-1541723
Board of directors
-
Farzad Nazem · DirectorSince 2023
- Since 2023
-
Karen Akinsanya · DirectorSince 2023
-
Matthew L. Posard · DirectorSince 2023
-
Matthew S. McIlwain · DirectorSince 2023
-
Melissa B. Epperly · DirectorSince 2023
-
Michael Seth Altman · DirectorSince 2023
-
Parag Mallick · Director · Chief ScientistSince 2023
-
Sujal M. Patel · Director · CEO, President, and SecretarySince 2023
-
Vijay Satyanand Pande · DirectorSince 2023
Chief executives
Director election results
Annual meeting of June 17, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
96.6%
-
96.7%
Board connections
5 of this board's directors also sit on 10 other boards.
- via Joseph Edelman and Michael Seth Altman
- via Joseph Edelman
- via Vijay Satyanand Pande
- via Matthew L. Posard
- via Joseph Edelman
- via Joseph Edelman
- via Joseph Edelman
- via Joseph Edelman
- via Melissa B. Epperly
- via Joseph Edelman
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $65,250
- 1 purchase by 1 insider
- Sold, last 12 months
- $11,750,000
- 2 sales by 1 insider
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 2, 2026 | AH Bio Fund II, L.P. 10% owner | Open-market sale | −4,615,974 | $2.35 | $10,847,539 |
| Jun 2, 2026 | AH Bio Fund II, L.P. 10% owner | Open-market sale | −384,026 | $2.35 | $902,461 |
| Mar 4, 2026 | Sujal M. Patel Director, Officer (CEO, President, and Secretary), 10% owner | Open-market purchase | +25,000 | $2.61 | $65,250 |
| Nov 6, 2025 | Suzuki Kentaro Officer (Chief Marketing Officer) | Open-market purchase | +4,000 | $1.49 | $5,960 |
| Sep 8, 2025 | Sujal M. Patel Director, Officer (CEO, President, and Secretary), 10% owner | Open-market purchase | +83,500 | $0.68 | $56,780 |
| Sep 5, 2025 | Sujal M. Patel Director, Officer (CEO, President, and Secretary), 10% owner | Open-market purchase | +116,500 | $0.67 | $78,055 |
| Sep 4, 2025 | Murphy Matthew B. Officer (General Counsel) | Open-market purchase | +20,000 | $0.64 | $12,800 |
| May 29, 2025 | Mowry Anna Officer (CFO and Treasurer) | Open-market purchase | +15,000 | $0.77 | $11,550 |
| May 12, 2025 | Parag Mallick Director, Officer (Chief Scientist), 10% owner | Open-market purchase | +1,500 | $0.73 | $1,095 |
| May 8, 2025 | Parag Mallick Director, Officer (Chief Scientist), 10% owner | Open-market purchase | +12,000 | $0.73 | $8,760 |
| Mar 20, 2025 | Sujal M. Patel Director, Officer (CEO, President, and Secretary), 10% owner | Open-market purchase | +23,933 | $1.00 | $23,933 |
| Mar 19, 2025 | Sujal M. Patel Director, Officer (CEO, President, and Secretary), 10% owner | Open-market purchase | +53,300 | $0.99 | $52,767 |
| Sep 23, 2024 | Godwin Mary E. Officer (Senior VP, Operations) | Option exercise | +47,031 | $0.46 | $21,634 |
| Sep 23, 2024 | Godwin Mary E. Officer (Senior VP, Operations) | Open-market sale | −47,031 | $2.87 | $134,979 |
| Sep 17, 2024 | Godwin Mary E. Officer (Senior VP, Operations) | Option exercise | +35,000 | $0.46 | $16,100 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Nautilus Biotechnology Inc.
Who is the CEO of Nautilus Biotechnology Inc.?
Sujal M. Patel is Nautilus Biotechnology Inc.'s CEO, President, and Secretary.
How many directors are on Nautilus Biotechnology Inc.'s board?
Nautilus Biotechnology Inc.'s board has 10 directors: Farzad Nazem, Joseph Edelman, Karen Akinsanya, Matthew L. Posard, Matthew S. McIlwain, Melissa B. Epperly, Michael Seth Altman, Parag Mallick, Sujal M. Patel and Vijay Satyanand Pande.
Are Nautilus Biotechnology Inc. insiders buying or selling shares?
Over the last 12 months, Nautilus Biotechnology Inc. insiders bought $65,250 of shares in 1 purchase and sold $11.8 million of shares in 2 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="nautilus-biotechnology-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.